Neumora Therapeutics, Inc. Income Statement
Concept
Total Revenue
YoY
Cost of Goods Sold (COGS)
Gross Profit
Operating expenses
Selling, General & Administrative
Research & Development
Operating Income
Interest Expense
Income Before Tax
Tax Provision
Net Income
YoY
Total Expenses
Net Interest Income
EBITDA
Reconciled Depreciation
EBIT
2023
2022
2021
2020
2019
0M
-
0M
0M
252M
45M
207M
-252M
0M
-236M
0M
-236M
80.23%
0M
17M
0M
1M
0M
0M
-
0M
0M
136M
31M
105M
-136M
0M
-131M
0M
-131M
-44.84%
136M
5M
-135M
1M
-136M
0M
-
0M
0M
237M
25M
213M
-237M
0M
-237M
0M
-237M
139.05%
237M
0M
-237M
1M
-237M
0M
-
0M
0M
96M
8M
87M
-96M
0M
-99M
0M
-99M
139.05%
96M
0M
-95M
0M
-96M
0M
-
0M
0M
0M
0M
0M
0M
0M
0M
0M
0M
139.05%
0M
0M
0M
0M
0M
Concept
Total Revenue
YoY
Cost of Goods Sold (COGS)
Gross Profit
Operating expenses
Selling, General & Administrative
Research & Development
Operating Income
Interest Expense
Income Before Tax
Tax Provision
Net Income
YoY
Total Expenses
Net Interest Income
EBITDA
Reconciled Depreciation
EBIT
4Q2023
3Q2023
2Q2023
1Q2023
4Q2022
3Q2022
2Q2022
1Q2022
4Q2021
3Q2021
2Q2021
1Q2021
4Q2020
0M
-
0M
0M
114M
11M
103M
-114M
0M
-108M
0M
-109M
286.31%
114M
6M
-114M
0M
-114M
0M
-
0M
0M
57M
15M
42M
-57M
0M
-53M
0M
-53M
80.71%
57M
4M
-57M
0M
-57M
0M
-
0M
0M
0M
0M
0M
0M
0M
0M
0M
0M
-100.00%
0M
0M
0M
0M
-42M
0M
-
0M
0M
0M
0M
0M
0M
0M
0M
0M
0M
-100.00%
0M
0M
0M
0M
-39M
0M
-
0M
0M
31M
7M
24M
-31M
0M
-28M
0M
-28M
4.36%
31M
2M
-31M
0M
-31M
0M
-
0M
0M
31M
8M
23M
-31M
0M
-29M
0M
-29M
-83.52%
31M
1M
-30M
0M
-31M
0M
-
0M
0M
31M
8M
24M
-31M
0M
-30M
0M
-30M
78.54%
31M
1M
-31M
0M
-31M
0M
-
0M
0M
43M
8M
35M
-43M
0M
-43M
0M
-43M
181.25%
43M
0M
-43M
0M
-43M
0M
-
0M
0M
27M
8M
19M
-27M
0M
-27M
0M
-27M
34.86%
27M
0M
-26M
0M
-27M
0M
-
0M
0M
178M
7M
171M
-178M
0M
-178M
0M
-178M
34.86%
178M
0M
-178M
0M
-178M
0M
-
0M
0M
17M
6M
11M
-17M
0M
-17M
0M
-17M
34.86%
17M
0M
-17M
0M
-17M
0M
-
0M
0M
15M
4M
12M
-15M
0M
-15M
0M
-15M
34.86%
15M
0M
-15M
0M
-15M
0M
-
0M
0M
20M
4M
15M
-20M
0M
-20M
0M
-20M
34.86%
20M
0M
-19M
0M
-20M